By Nate Raymond
(Reuters) - Johnson & Johnson suffered its first trial loss in a lawsuit claiming its talc-based products including Johnson's Baby Powder contain cancer-causing asbestos, with a New Jersey jury on Thursday ordering J&J and another company to pay $37 million in damages.
The verdict of liability in Middlesex County Superior Court in New Brunswick came as J&J fights thousands of cases claiming its talc products can also cause ovarian cancer. The jury found J&J and another company liable after more than two months of trial.
The lawsuit was brought by New Jersey resident Stephen Lanzo, who said he developed mesothelioma after inhaling dust that was generated through his regular use of J&J talc powder products since his birth in 1972.
Mesothelioma is a deadly form of cancer closely associated with exposure to asbestos. It affects the delicate tissue that lines body cavities, most often around the lungs, but also in the abdomen and elsewhere.
The jury awarded Lanzo $30 million and his wife $7 million in compensatory damages. It found J&J was responsible for 70 percent of the damages and said a unit of France-based Imerys SA , its talc supplier, was responsible for 30 percent.
The jury will return on Tuesday for further proceedings to determine whether to award punitive damages, according to an online broadcast of the trial by Courtroom View Network.
J&J denied the allegations and says Johnson's Baby Powder does not contain asbestos or cause cancer.
J&J in a statement said it was disappointed but would withhold further comment until the trial's completion. Gwen Myers, an Imerys spokeswoman, said Imerys plans to appeal and is confident talc did not cause Lanzo's cancer.
The Lanzos did not respond to requests for comment.
J&J, based in New Brunswick, New Jersey, faces talc-related lawsuits by 6,610 plaintiffs nationally, largely based on claims it failed to warn women about the risk of developing ovarian cancer by using its products for feminine hygiene.
In five trials in Missouri involving ovarian cancer lawsuits, juries found J&J liable four times and awarded the plaintiffs a total of $307 million. In California, a jury awarded a now-deceased woman $417 million.
But in October, a Missouri appellate court threw out the first verdict there for $72 million and a California judge tossed the $417 million verdict. J&J is seeking to reverse the other verdicts.
Asbestos claims are a more recent challenge for J&J. It won the only other asbestos-related trial in November when a Los Angeles Superior Court jury ruled in its favour.
(This version of the story corrects headline to show case was J&J's first trial loss in an asbestos-related case involving talc, not first loss in talc cancer lawsuit and first paragraph to say both J&J and another company have been ordered to pay $37 million, not just J&J.)
(Reporting by Nate Raymond in Boston; Editing by Susan Thomas and Leslie Adler)
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
